⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 18, 2024Journal of Nuclear MedicineOpen Access

[¹⁷⁷Lu]Lu-Prostate-Specific Membrane Antigen-617 in a Patient with Metastatic Castration-Resistant Prostate Cancer and Status After Bilateral Nephrectomy

Yu-Yi Huang Ting-Chum Lin Shih-Han Yang Lan-Shih Lai Ling-Man Hung Ming-Hsin Li Kuo‐Cheng Huang

View Full Paper

Ask AI

Bookmark

Share

Abstract

In a 79-y-old man with metastatic castration-resistant prostate cancer and a history of bilateral nephrectomy for renal cell carcinoma, undergoing thrice-weekly hemodialysis, [68Ga]Ga-PSMA-11 PET revealed intense prostate-specific membrane antigen–avid lesions ([Fig. 1A][1]). He received 2 cycles

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Huang et al. (2024) studied this question.

synapsesocial.com/papers/68e6e8b6b6db643587663f59 https://doi.org/10.2967/jnumed.124.267533

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Complete Resolution of Locally Advanced Prostate Cancer After Molecular Endoradiotherapy With 177Lu-PSMA2024 · 3 citations
2<sup>177</sup>Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and EfficacyCohort Study · 2016 · 525 citations
3Spectacular effect of [177Lu]Lu-PSMA-617 therapy in a patient with hormone-resistant prostate cancer after failure of other therapeutic options.2025
4Radionuclide Therapy With 177Lu-PSMA in a Patient With Hepatocellular Carcinoma2024 · 6 citations
5Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate CancerOriginal Research · 2021 · 2,829 citations